Calderol: Medgend

Calderol FDA Approved Drugs

RAYALDEE [Calcifediol^{C₂₇H₄₄O₂H₂O}]

0.03mg (oral capsule, extended release)

Opko Ireland Global^{Jun 17, 2016}

Administration of 25-hydroxyvitamin d3 by controlled release.
Treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease using controlled release, oral 25-hydroxyvitamin d.
Use of controlled release 25-hydroxyvitamin d in treating secondary hyperparathyroidism in patients having chronic kidney disease.
Use of extended release oral 25-hydroxyvitamin d3 in treating secondary hyperparathyroidism in adult patients having chronic kidney disease stage 3 or stage 4.
Use of sustained release 25-hydroxyvitamin d in treating patients having 25-hydroxyvitamin d insufficiency or deficiency.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.